See more : Nichirin Co., Ltd. (5184.T) Income Statement Analysis – Financial Results
Complete financial analysis of Verrica Pharmaceuticals Inc. (VRCA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verrica Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Athlon Acquisition Corp. (SWETW) Income Statement Analysis – Financial Results
- Minerals 260 Limited (MI6.AX) Income Statement Analysis – Financial Results
- Plaza Centers N.V. (PLZ.WA) Income Statement Analysis – Financial Results
- Ritco Logistics Limited (RITCO.BO) Income Statement Analysis – Financial Results
- Xiangyang BOYA Precision Industrial Equipments Co., Ltd (300971.SZ) Income Statement Analysis – Financial Results
Verrica Pharmaceuticals Inc. (VRCA)
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5.12M | 9.03M | 12.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 746.00K | 725.00K | 472.00K | 229.00K | 257.20K | 20.29K | 0.00 | 0.00 |
| Gross Profit | 4.38M | 8.31M | 11.53M | -229.00K | -257.20K | -20.29K | 0.00 | 0.00 |
| Gross Profit Ratio | 85.44% | 91.97% | 96.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.30M | 12.20M | 15.93M | 15.67M | 15.44M | 12.83M | 3.73M | 1.71M |
| General & Administrative | 0.00 | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 47.31M | 17.41M | 26.98M | 24.51M | 14.64M | 9.05M | 727.00K | 204.00K |
| Other Expenses | 2.54M | -58.00K | 0.00 | -1.00K | 1.87M | -1.00K | 0.00 | 0.00 |
| Operating Expenses | 70.14M | 29.60M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Cost & Expenses | 70.88M | 30.33M | 42.91M | 40.18M | 30.08M | 21.88M | 4.46M | 1.91M |
| Interest Income | 2.74M | 476.00K | 123.00K | 521.00K | 1.88M | 1.23M | 0.00 | 0.00 |
| Interest Expense | 3.96M | 2.17M | 4.30M | 3.03M | 0.00 | 0.00 | 2.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 718.00K | 472.00K | 229.00K | 257.20K | 20.29K | 4.46M | 1.91M |
| EBITDA | -62.20M | -21.60M | -30.31M | -39.43M | -30.08M | -20.63M | -4.46M | -1.91M |
| EBITDA Ratio | -1,213.84% | -231.16% | -256.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -65.76M | -21.30M | -30.91M | -40.18M | -30.08M | -21.88M | -4.46M | -1.91M |
| Operating Income Ratio | -1,283.35% | -235.78% | -257.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.24M | -3.19M | -4.17M | -2.51M | 1.87M | 1.23M | -2.00K | 0.00 |
| Income Before Tax | -67.00M | -24.49M | -35.08M | -42.69M | -28.21M | -20.65M | -4.46M | -1.91M |
| Income Before Tax Ratio | -1,307.47% | -271.11% | -292.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.19M | 3.82M | 2.80M | -257.00K | 1.23M | -4.46M | -1.91M |
| Net Income | -67.00M | -27.68M | -38.90M | -45.50M | -27.95M | -20.65M | -4.46M | -1.91M |
| Net Income Ratio | -1,307.47% | -306.44% | -324.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| EPS Diluted | -1.48 | -0.81 | -1.44 | -1.82 | -1.12 | -1.41 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
| Weighted Avg Shares Out (Dil) | 45.34M | 34.16M | 27.04M | 25.00M | 24.90M | 14.66M | 19.95M | 19.95M |
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
Here's What Insiders Are Buying to Wrap Up the Year
Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
Source: https://incomestatements.info
Category: Stock Reports